# TCE

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/tce
Canonical HTML page: https://getbiobrief.com/entity/tce

## Timeline

- **2026-12-31**: Profitability Target — Antengene aims to achieve its first full year of profitability.
- **2026-04-01**: AACR 2026 — Antengene scheduled to present data on next-generation ADCs and TCEs.
- **2026-03-20**: 2025 FY Results — Company announces full-year results and confirms shift toward 2026 profitability.
- **2026-03-04**: UCB Partnership — Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.

## Recent coverage (1 stories)

### Antengene Eyes 2026 Profitability Following Landmark TCE Out-Licensing Deal
2026-03-20 14:54:16 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Full story: https://getbiobrief.com/story/antengene-2025-results-tce-licensing-profitability

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.